Research

Energy balance

Long-term use of GLP-1 receptor agonists (GLP-1RAs) reduces the incidence of knee surgery and slows cartilage loss velocity in knee osteoarthritis (KOA) patients with comorbid type 2 diabetes, primarily mediated by significant weight loss rather than direct anti-inflammatory effects.

If you have knee osteoarthritis and type 2 diabetes, using GLP-1RAs (like semaglutide or liraglutide) for at least two years can significantly reduce your risk of needing knee surgery and slow down cartilage wear. This benefit comes mainly from the weight loss these drugs cause, which reduces stress on your knees. While they also help with pain, the structural protection is largely weight-dependent. To maximize benefits, combine GLP-1RA therapy with resistance training to preserve muscle mass.

GoodSupportsHIGH confidence
The association between GLP-1RA exposure and decreased incidence of knee surgery was mediated by weight reduction (mediation proportion: 32.1%), instead of glycaemic control (too small to calculate).
Hongyi Zhu et al. · Annals of the Rheumatic Diseases · 2023

Why this rating

Large prospective observational cohort (n=1807) with long follow-up (mean 4.9 years), adjusted for multiple covariates, but not a randomized controlled trial.

Source

Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort

Hongyi Zhu et al. · Annals of the Rheumatic Diseases · 2023

DOI 10.1136/ard-2023-223845

cohort · n=1807Cited 109×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →